SFC

Découvrez l'article du mois de décembre des Archives of Cardiovascular Diseases, la revue scientifique en anglais de la SFC : 
Bioprosthetic leaflet thrombosis and reduced leaflet motion after transcatheter aortic valve replacement: A systematic review and meta-analysis
Vincent Roule, Paul Guedeney, Johanne Silvain, Farzin Beygui, Michel Zeitouni, Sabato Sorrentino, Mathieu Kerneis, Olivier Barthelemy, Frédéric Beaupré, Jean-Jacques Portal, Eric Vicaut, Gilles Montalescot, Jean-Philippe Collet

Abstract


Background: Leaflet thrombosis and reduced leaflet motion have become a concern with the expanding use of transcatheter aortic valve replacement in lower-risk patients.

Aims: To assess the proportions, predictors and clinical impact of leaflet thrombosis and reduced leaflet motion after transcatheter aortic valve replacement.

Methods: We performed a meta-analysis of studies assessing the proportions of and/or clinical outcomes according to the presence of leaflet thrombosis after transcatheter aortic valve replacement identified with computed tomography and/or echocardiography.

Results: Fifty-three studies, representing 25,258 patients undergoing transcatheter aortic valve replacement, were considered. The proportion of leaflet thrombosis was 5.2% overall, and was higher in computed tomography versus echocardiography (16.4% vs. 1.1%, respectively); reduced leaflet motion was identified in 11% of patients with four-dimensional computed tomography. Intra-annular bioprostheses were associated with a higher proportion of leaflet thrombosis, whereas chronic oral anticoagulation was protective for leaflet thrombosis in both computed tomography and echocardiographic studies (9.7% vs.17.5%; relative risk [RR]: 0.51, 95% confidence interval [95% CI]: 0.37–0.71 and 0.9% vs. 2.7%; RR: 0.22, 95% CI: 0.06–0.79, respectively) and for reduced leaflet motion (2.5% vs. 12.4%; RR: 0.32, 95% CI: 0.13–0.76).Leaflet thrombosis was not associated with an increased risk of death, but with a higher risk of stroke incomputed tomography studies (2.8% vs. 2.4%; RR: 1.63, 95% CI: 1.05–2.55), a difference more pronounced when considering reduced leaflet motion (3.5% vs. 1.7%; RR: 2.39, 95% CI: 0.63–8.34).

Conclusions: The proportion of leaflet thrombosis is highly variable according to the screening approach, the type of valve and the use of oral anticoagulation. The occurrence of cerebral events is increased when leaflet thrombosis and/or reduced leaflet motion are diagnosed, but leaflet thrombosis has no impact on survival.

Keywords


• Transcatheter aortic valve replacement
• Valve thrombosis
• Imaging
• Stroke

Nos suggestions d’actualités

Les actualités Cardio Online

La muvalaplin : nouvel inhibiteur de la lp(a) par voie orale

21 novembre 2024

Pas de supériorité d’un système d’aide à la décision pour optimiser les thérapies hypolipémiantes dans le post SCA

21 novembre 2024

Efficacité et sécurité d’emploi de l’obicetrapib, un nouvel inhibiteur de la CETP

21 novembre 2024

Zerlasiran, encore un nouvel antiLp(a) en développement

21 novembre 2024

L’edoxaban pour la prévention de thrombose valvulaire

20 novembre 2024

22/11/2024
Actualités SFC
Veille bibliographique

La SFC a lu pour vous : Veille bibliographique - 22/11/24

21/11/2024
Actualités Communautés
Newsletter

Newsletter de la SFHTA - Novembre 2024

21/11/2024
Actualités Congrès
Congrès

Impact environnemental de la cardiologie : Participez à notre enquête nationale !